Cartilage Injury Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cartilage injury treatment encompasses the medical and surgical management of damage to articular (hyaline) cartilage — the smooth, specialised connective tissue that lines the ends of bones within synovial joints, providing frictionless movement and absorbing mechanical forces. Articular cartilage has minimal intrinsic healing capacity because it lacks blood vessels, lymphatics, and direct nerve supply; once damaged, it does not heal spontaneously like other tissues. Untreated cartilage defects progress over years to decades to generalised osteoarthritis, joint pain, and functional limitation.

Cartilage injuries range from surface softening and fibrillation (Grade I–II Outerbridge) through partial-thickness fissuring (Grade III) to full-thickness defects exposing subchondral bone (Grade IV). They occur most commonly in the knee — particularly the medial femoral condyle, trochlea, and patella — but also affect the hip (femoral head, acetabulum), ankle (talar dome), elbow, and shoulder. Causes include acute trauma (sports injuries, falls), repetitive mechanical overload, osteochondral dissecans (OCD), and avascular necrosis.

Treatment selection is guided by lesion size, depth, location, and patient age and activity level: lesions below 2 cm² may respond to microfracture marrow stimulation; lesions of 2–4 cm² in young active patients are best addressed by autologous chondrocyte implantation (ACI) or osteochondral autograft transfer (OATS); larger lesions may require fresh osteochondral allograft. A multidisciplinary approach involving sports medicine, orthopaedic surgery, physiotherapy, and imaging is standard.

Focal articular cartilage defects of the knee — particularly the medial femoral condyle (most common site), lateral femoral condyle, trochlea, and patella — are the primary indication for surgical cartilage repair. These arise from sports injuries (direct blow, twisting), osteochondral dissecans in adolescents and young adults (in whom the fragment may be repaired and fixed rather than excised), and symptomatic full-thickness Grade III–IV lesions in active patients below 50–55 years who wish to avoid or delay joint replacement. Chondral injuries are frequently associated with other intra-articular pathology — ACL tears, meniscal tears, malalignment — that must be addressed concurrently or staged to optimise the mechanical environment for cartilage repair.

Talar dome osteochondral defects — common after ankle sprains and fractures — are a well-established indication for arthroscopic microfracture or OATS when persistent ankle pain and swelling persist beyond three to six months of conservative treatment. Femoral head and acetabular cartilage lesions associated with femoroacetabular impingement (FAI) may be addressed at the time of hip arthroscopy. Chondral defects in overhead athletes affecting the elbow (capitellum OCD) represent another important subgroup, managed with arthroscopic debridement and marrow stimulation or OATS depending on fragment status.

Ideal candidates for surgical cartilage repair are young to middle-aged patients (typically below 50 years) with symptomatic focal full-thickness chondral defects (Grade III–IV), isolated lesion size amenable to the chosen technique, normal or corrected mechanical alignment of the limb, stable ligaments (or plans for concurrent stabilisation), preserved menisci (or plans for concurrent repair), and normal or near-normal BMI (below 35 kg/m²). Patient motivation for the rehabilitation programme — which is extensive and critical to outcome — is a key selection criterion.

Contraindications to cartilage repair include generalised osteoarthritis (diffuse cartilage loss in multiple compartments), inflammatory arthropathy (rheumatoid, psoriatic), uncorrected malalignment (varus or valgus deformity more than three degrees without concurrent realignment osteotomy), BMI above 35 kg/m², failure of a previous cartilage repair attempt in the same location, active infection, and insufficient bone stock beneath the defect for marrow stimulation. Older patients above 50–55 years are generally better served by unicompartmental or total knee replacement if the arthritic burden is significant, though highly active patients with isolated lesions may be offered cartilage repair on a case-by-case basis.

Microfracture — making multiple small perforations into the subchondral bone at the base of the cartilage defect using an arthroscopic awl or drill — stimulates mesenchymal stem cell migration from bone marrow into the defect, forming a fibrocartilaginous repair tissue. It is the simplest and least expensive cartilage repair technique, appropriate for defects below 2 cm² in well-selected patients. Short-term outcomes are good (70–80% satisfactory at two years) but deterioration occurs in many patients beyond five years as the fibrocartilage repair tissue lacks the mechanical properties of native hyaline cartilage.

Autologous chondrocyte implantation (ACI) is a two-stage procedure: cartilage is arthroscopically harvested, chondrocytes are cultured in a laboratory for four to six weeks, and then reimplanted into the prepared defect in a second open or arthroscopic procedure. Matrix-assisted ACI (MACI — Vericel) uses a collagen membrane seeded with the expanded chondrocytes, producing hyaline-like repair tissue with superior mechanical properties to microfracture fibrocartilage. OATS (osteochondral autograft transfer system) transplants one or more cylindrical osteochondral plugs from non-load-bearing regions of the knee (femoral condyle margins, trochlea notch) to fill the defect, providing immediate hyaline-like cartilage coverage. Fresh osteochondral allograft transplantation uses size-matched donor bone-cartilage from a tissue bank for large defects (above 4 cm²) not treatable with autograft.

Surgical cartilage repair provides significant pain relief and functional restoration in appropriately selected patients. ACI and MACI demonstrate superior long-term outcomes to microfracture for larger defects (above 2 cm²) and in physically active patients, with over 70–80% of patients reporting satisfactory outcomes at five to ten years. The SUMMIT trial demonstrated superiority of MACI over microfracture for medial femoral condyle defects above 3 cm² at two years. Osteochondral autograft transfer provides immediate hyaline cartilage coverage and is particularly effective for smaller talar dome and femoral condyle defects, with approximately 80–90% satisfactory outcomes at medium-term follow-up.

Successful cartilage repair delays or prevents the progression to generalised osteoarthritis and the need for joint replacement — a particularly important benefit in patients below 50 years for whom total knee replacement has a higher lifetime revision rate. Return to sports — including running, jumping, and pivoting activities — is achievable in 60–80% of athletes at twelve to eighteen months after ACI/MACI or OATS, with appropriate staged rehabilitation. Pain reduction, improved joint function scores, and cartilage fill on MRI are documented across multiple prospective studies and randomised trials.

Microfracture has low surgical risk but carries the clinical risk of fibrocartilage repair tissue deterioration over five to ten years, with approximately 50% of patients demonstrating radiological worsening beyond seven years. Subchondral cyst formation and subchondral bone overgrowth (intralesional osteophyte) are specific complications of microfracture, potentially compromising the subchondral bone plate and complicating subsequent ACI if revision surgery is required. ACI requires two surgical procedures (harvest and implantation), with the attendant risks of each. Graft hypertrophy — overgrowth of the implanted chondrocytes causing a raised fibrous mass within the joint — occurred in approximately 10–20% of earlier periosteal-covered ACI but is much less common with membrane-covered MACI.

OATS donor site morbidity — pain at the harvest site on the non-load-bearing femoral condyle margin — affects 5–10% of patients and is usually temporary. Graft subsidence (collapse of the osteochondral plug) and graft delamination (separation of the cartilage cap from the bone plug) are uncommon but serious complications requiring revision. For allograft procedures, disease transmission risk is extremely small with modern tissue banking protocols (below 1 in 1 million), but graft failure from immunological rejection or avascular necrosis of the bone component occurs in 5–10% at ten years. Failure to address concomitant pathology (malalignment, ligament instability) substantially increases the failure rate of any cartilage repair technique.

Recovery after cartilage repair surgery is measured in months, not weeks, reflecting the biological timeline of cartilage maturation. After microfracture, patients are non-weight-bearing for six to eight weeks, using crutches and a continuous passive motion (CPM) machine for six to eight hours daily to promote fibrocartilage fill without mechanical loading. After ACI/MACI, non-weight-bearing for eight to twelve weeks transitions to partial and full weight-bearing over months; return to sports takes twelve to eighteen months. After OATS, weight-bearing progression is more rapid (full weight-bearing by six to eight weeks) but return to demanding sports takes nine to twelve months.

MRI at six to twelve months documents cartilage fill and integration of the repair tissue. A graduated physiotherapy programme progresses through range-of-motion restoration, muscle strengthening (particularly quadriceps and VMO rehabilitation), proprioception retraining, and sport-specific exercise. Functional milestones — jogging at three to six months, cutting and pivoting at nine to twelve months, return to sport at twelve to eighteen months — are guided by objective strength testing and clinical assessment. Addressing any associated pathology (meniscal repair, ligament reconstruction, alignment correction) is essential for the durability of cartilage repair.

Cartilage repair surgery costs vary significantly by technique. Arthroscopic microfracture in the United States costs USD 10,000–20,000 including anaesthesia and facility fees. ACI/MACI requires two procedures plus cell culture laboratory costs — total USD 30,000–70,000 in the US. Osteochondral allograft transplantation costs USD 30,000–60,000. In India, high-quality arthroscopic microfracture is available at Apollo Hospitals, Fortis, and Manipal for USD 2,000–6,000. MACI is less widely available in developing countries due to cell culture infrastructure requirements, but OATS is available at several tertiary orthopaedic centres in India for USD 5,000–12,000.

Thailand (Bumrungrad, Vejthani) offers cartilage surgery for USD 6,000–18,000; Turkey (Acibadem) USD 5,000–15,000. Patients seeking cartilage repair abroad should verify that the orthopaedic surgeon has subspecialty sports medicine or cartilage surgery training, high-volume experience in the specific technique required, and that the centre has a dedicated rehabilitation programme for the six-to-eighteen month post-operative recovery period. Given the length of rehabilitation required, proximity to home for follow-up care is an important practical consideration for international patients.

Conservative management is appropriate for smaller lesions, older patients, and those not prepared for the prolonged recovery. Physiotherapy targeting quadriceps strengthening, neuromuscular rehabilitation, and activity modification reduces symptoms and functional limitation from chondral defects without addressing the defect itself. Intra-articular corticosteroid injections provide short-term pain relief for inflammatory symptoms but do not promote cartilage repair. Hyaluronic acid injections improve lubrication and reduce synovial inflammation; evidence for structural modification is lacking but symptom relief is well-documented for mild to moderate disease. Platelet-rich plasma (PRP) injections are increasingly used for early to moderate chondral disease, with growing evidence for symptom reduction though no definitive cartilage regeneration. For older patients above 50–55 years with advanced chondral damage and established osteoarthritic changes, unicompartmental or total knee replacement provides more reliable and durable pain relief than cartilage repair.